CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
Press release
CROSSJECT advances on the development of ZEPIZURE® , its solution for epilepsy crises in children
Announces the effective calibration of ZENEO® for the use of ZEPIZURE® in the pediatric population.
CROSSJECT completed an echography clinical study allowing to determine and validate the targeted depth of injection in children as compared to adults.
Dijon, France 11 June 2025 (07h30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharma company in advanced phases of development and registration for ZEPIZURE® in adults, is progressing in the development of its pediatric version of ZEPIZURE®, branded ZEPIZURE® Junior.
According to the 2022 National Survey of Children's Health and as reported by the U.S. Centers for Disease Control and Prevention (CDC) on its 'Epilepsy Facts & Stats' pages, there are approximately 456,000 children with active epilepsy in the U.S. The active epilepsy population is defined as patients who are diagnosed and actively managed by a caregiver.
Under its contract with the Biomedical Advanced Research and Development Authority (BARDA), CROSSJECT completed a clinical echography study in a 90 adults and children (2-18 years old) to measure and compare the anatomical characteristics of thighs, i.e. the thickness of layers from skin to muscle (CJTCDZ2301, NCT06279689). In parallel CROSSJECT conducted studies on its ex-vivo experimental models that reconstitute the skin and the subcutaneous and muscle layers in children. These tests have successfully enabled the calibration of the pressure to be exerted by the ZENEO® device gas generators to expel the drug solution with the suitable penetration depth and confirmed the adequacy of the ZENEO® device in its 'Junior' mode.
Previous Human Factors studies had also included a significant number of children above 8 years of age and did successfully demonstrate their ability to use the autoinjector ZENEO® effectively.
« We are excited by this incremental innovation and the success in our product development. Pediatrics is strategic to CROSSJECT as we want to establish ZEPIZURE® as the standard of care early in this chronic condition. We look forward to advancing with the Food and Drug Administration (FDA) and having concrete clinical solutions to propose to the pediatric patient community », said Patrick ALEXANDRE, CEO of CROSSJECT.
About CROSSJECT
CROSSJECT SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharmaceuticals company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO® platform. CROSSJECT is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract* with BARDA. The Company's versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare skin or even through clothing. The Company's other products in developmentmainly include solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency indications.
* This project has been supported in whole or in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; BARDA, under contract number 75A50122C00031.
***
For further information, please contact:
Investor Relationsinvestors@crossject.com
Attachment
CROSSJECT advances on the development of ZEPIZURE® Junior
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
2 hours ago
- Forbes
AI Will Provide Much Needed Shortcut In Finding Earthlike Exoplanets
In the search for earthlike planets, AI is playing more and more of a role. But first one must define what is meant by earthlike. That's not an easy definition and is the cause of much confusion in the mainstream media. When planetary scientists say that a planet is earthlike, they really mean it's an earth mass planet that lies in the so-called habitable zone of any given extrasolar planetary system. That's loosely defined as the zone in which a given planet can harbor liquid water at its surface. But there's no guarantee that it has oceans, beaches, fauna, flora, or anything approaching life. Yet Jeanne Davoult, a French astrophysicist at the German Aerospace Center (DLR) in Berlin, is at the vanguard of using artificial intelligence to speed up the process of finding earthlike planets using AI modeling and algorithms that would boggle the minds of mere mortals. In a recent paper, appearing in the journal Astronomy & Astrophysics, Davoult, the paper's lead author writes that the aim is to use AI to predict which stars are most likely to host an earthlike planet. The goal is use AI to avoid blind searches, minimize detection times, and thus maximize the number of detections, she and colleagues at the University of Bern write. Using a previous study on correlations between the presence of an earthlike planet and the properties of its system, we trained an AI Random Forest, a machine learning algorithm, to recognize and classify systems as 'hosting an earthlike planet' or 'not hosting an earthlike planet,' the authors write. For planetary detection, we try to identify patterns in data sets, and patterns which correspond to planets, Davoult tells me via telephone. Understanding and anticipating where earthlike planets form first, and thus targeting observations to avoid blind searches, minimizes the average observation time for detecting an earthlike planets and maximizes the number of detections, the authors write. But among the estimated 6000 exoplanets thus detected in the last 30 years, only some 20 systems with at least one earthlike planet have been found, says Davoult. In fact, stars smaller than the Sun --- such as K-spectral type dwarfs as well as the ubiquitous red dwarf M-spectral type stars which make up most of the stars in the cosmos, all have longer lifetimes than our own G-spectral type star. Thus, because of their long stellar lifetimes, it's probably more likely for intelligent life to develop around these K and M types of stars, says Davoult. We are also focusing a lot on M dwarfs because it's easier to detect an earthlike planet around the stars than around sun like stars, because the habitable zone is closer to the stars, so the orbital period is shorter, she says. The three populations of synthetic systems used in this study differ only in the mass of the central star, the authors write. This single difference directly influences the mass of the protoplanetary disk and thus the amount of material available for planet formation, note the authors. As a result, the three populations exhibit different occurrences and properties for the same type of planet, highlighting the importance of studying various types of stars, they write. We have developed a model using a Random Forest Classifier to predict which known planetary systems are most likely to host an earthlike planet, the authors write. It's hard to really compare synthetic planetary populations and real planetary populations, because we know that our model is not perfect, says Davoult. But if you just take the big pattern at the system level, then I'm convinced it's a very powerful tool, she says. If we observe a planet within a given solar system, it doesn't mean that we've detected all the planets in this planetary system, says Davoult. That's because an earthlike planet might be a bit too far away from the star, or too small to detect, she says. In contrast, my model takes what we already know about planetary system and tells us if there is a possibility for an undetected earthlike planet to exist in the same planetary system, says Davoult. Davoult is specifically looking for terrestrial planets in the habitable zone of their parent stars. The very first step is just to detect them and create a database of earthlike planets, even if we have no clue about the composition of their atmospheres, says Davoult.
Medscape
3 hours ago
- Medscape
RCGP Urges Support to Save Declining GP Partnership Model
The Royal College of General Practitioners (RCGP) has warned that GP partnerships are under threat, as the number of partners in England has dropped by 25% over the past decade. In a new report, the college urged action to 'break down barriers to partnership' and called for modernisation of the model to make it more attractive to younger doctors. While the RCGP reaffirmed its support for the independent contractor model, it said there was 'room for modernisation and innovation', and backed ' a mixed economy' of contractual models to deliver general practice. Shift in Workforce Between 2015 and 2025, the number of GP partners in England fell from 24,491 to 18,367. Over the same period, the number of salaried GPs rose by 81%, from 10,270 in September 2015 to 18,557 in December 2024. As of June 2024, GP partners were a minority among fully qualified GPs for the first time. The most significant drop in partnership was seen in younger doctors. Among GPs aged 30-34, numbers fell by 72.9%. The only age group to show growth was those aged 60-64, up by 19.5%. Barriers to Partnership Rising workload, administrative burdens, and concerns about financial risk were cited as major deterrents to partnership. Professor Kamila Hawthorne, RCGP chair, said that many GPs were discouraged by the unlimited personal liability that comes with being a partner. She also pointed to the responsibilities of owning or leasing premises and managing staff, especially as patient demand increases. Exploring Alternatives The RCGP report explored alternative business models that could support general practice, including limited companies, limited liability partnerships (LLPs), and community benefit societies. The college maintained that partnerships still offered flexibility and potential for innovation, particularly if financial and workload pressures could be reduced. In 2024, more than half (55%) of RCGP members said they would be more likely to consider partnership if financial risks were lower. A review by Lord Darzi highlighted the financial discipline of GP partnerships, noting that they could not run large deficits like other parts of the NHS. Earlier this year, the Nuffield Trust described the current GP partnership model as 'withering'. The health think tank warned that the government's plans to improve GP access were at risk due to the fall in partner numbers. Thea Stein, chief executive of the Nuffield Trust, told Medscape News UK : 'It is hard to see partnership being the dominant model in the future.' She called for support where the model works well, but said new models must also be explored. Hawthorne maintained that 'there are elements of the traditional GP partnership that can be improved and modernised, while retaining its core strengths'. The GP partnership model has huge benefits for the NHS and for patients, she added. Government Response A Department of Health and Social Care (DHSC) spokesperson acknowledged the strengths of the partnership model, including efficiency, innovation, and continuity of care. 'However, we also recognise that this is not the only model delivering general practice,' the spokesperson told Medscape News UK . 'GP practices can choose to organise themselves in different ways and also provide good outcomes in terms of staff engagement and patient experience.'
Associated Press
3 hours ago
- Associated Press
Hematologists Set the Stage for Market Disruption as Next-Gen Hemophilia Therapies Gain Traction
EXTON, PA, June 12, 2025 (GLOBE NEWSWIRE) -- As the hemophilia landscape continues to transform, new research from Spherix Global Insights reveals a market on the cusp of significant evolution driven by innovation, physician receptivity, and an increasingly nuanced approach to patient care. The latest Market Dynamix™: Hemophilia (EU) 2025 report, based on feedback from 160 hematologists across the UK, France, Germany, Italy, and Spain, illuminates shifting treatment preferences and the widening role for advanced therapeutic options across hemophilia A and B. The study captures a broadening treatment mindset in a market historically dominated by factor replacement therapies. Although conventional agents have provided stability for many patients, Spherix data highlight an increasingly urgent unmet need, particularly among patients with inhibitors. In fact, patients with inhibitors represent the group for whom hematologists see the greatest opportunity for innovation. Products such as Alhemo (Novo Nordisk) and Qfitlia (Sanofi) are already entering the physician consciousness as promising options, with early prescribing experiences for Alhemo in Germany showing favorable clinical feedback. Importantly, European hematologists are signaling readiness to embrace novel mechanisms that deliver sustained efficacy and reduce treatment burden. Beyond Alhemo and Hympavzi, there is rising anticipation for agents like Qfitlia and Mim8 (Novo Nordisk). Gene therapy, once seen as aspirational, is becoming a more realistic consideration, especially in hemophilia B where therapeutic alternatives remain limited. CSL Behring's Hemgenix and BioMarin's Roctavian are drawing interest, albeit tempered by concerns around cost and long-term outcomes. Spherix data reveal a market increasingly driven not just by efficacy but by lifestyle alignment and convenience. This reflects a maturation of brand expectations, where baseline efficacy is presumed and differentiation hinges on quality-of-life enhancements. The move away from standard half-life (SHL) and even extended half-life (EHL) products is evident, particularly in hemophilia A, where agents like Hemlibra (Roche/Genentech) and Altuvoct/Altuviiio (Sanofi) are rapidly becoming standard practice. Underlying these trends is a broader shift in therapeutic philosophy: goals focus less and less on symptom control (which is assumed) while disease modification becomes centrally important, mirroring changes seen in other chronic specialty markets. Hematologists are prepared to make transitions, especially when options can seamlessly accommodate inhibitor development without requiring treatment change. For Hympavzi, Alhemo, and Qfitlia, upcoming Launch DynamixTM tracking among US hematologists (available June 13th) underlines similar themes, with projected prescribing steadily rising for these novel agents. Additional metrics included in launch tracking include impact of product features and manufacturer programs on prescribing, assessment of likely patient groups for initial product trialing, and perspectives on which brand(s) are likely displaced by newer market entrants. Ultimately, as the treatment paradigm continues to evolve, biopharma stakeholders seeking success in the hemophilia space will need to align not only with clinical outcomes but also with patient-centric attributes now prioritized in physician decision-making. Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents. Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. Sarah Hendry, Hematology Franchise Head Spherix Global Insights 4848794284 [email protected]
